KAG-308

PDF

A18389

5mg，10mg，50mg

Brand

AdooQ BioScience

Description

KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration.

Application

Reactivity

Website

頁面

Photos

BACK TO LIST
回到產品列表